Last updated: 11/04/2018 08:09:21

Single and repeat dose first time in human study for an intranasal H1/H3 dual antagonist in healthy male subjects

Request patient level data
GSK study ID
HHI110157
See study documents
Clinicaltrials.gov ID
NCT00694993
EudraCT ID
2007-005053-31
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A double-blind, placebo-controlled, randomized single dose escalation study and a double-blind, placebo-controlled, randomised parallel group 14-days once daily repeat dose study to investigate safety, tolerability and pharmacokinetics of an intranasal H1/H3 dual antagonist compound in healthy male subjects
Trial description: This is a double-blind, placebo-controlled, randomized single dose escalation study and a double-blind, placebo-controlled, randomised parallel group 14-days once daily repeat dose study to investigate safety, tolerability and pharmacokinetics of an intranasal H1/H3 dual antagonist compound in healthy male subjects.
Primary purpose:
Treatment
Trial design:
Sequential Assignment
Masking:
Not applicable
Allocation:
Randomized
Primary outcomes:

ECG monitoring during 24 hours after each dose in the single dose cohorts and on days 1 and 7 in the repeat dose cohorts.

Timeframe: during 24 hours after each dose in the single dose cohorts and on days 1 and 7 in the repeat dose cohorts

Heart rate and blood pressure changes over 24 hours after dosing in single and repeat dose cohorts

Timeframe: over 24 hours after dosing

Secondary outcomes:

Blood drug levels for GSK1004723 following single and repeat intranasal dosing

Timeframe: Pre-dose, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours

Interventions:
  • Drug: GSK1004723
  • Drug: Placebo
    • Enrollment:
    19
    Primary completion date:
    Not applicable
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Daley-Yates P, Ambery C, Sweeney L, Watson J, Oliver A, Mcquade B. The efficacy and tolerability of two novel H1/H3 receptor antagonists in seasonal allergic rhinitis. [Int Arch Allergy Immunol]. 2012;158:84-98.
    Medical condition
    Rhinitis, Allergic, Seasonal
    Product
    GSK1004723
    Collaborators
    Not applicable
    Study date(s)
    December 2007 to May 2008
    Type
    Interventional
    Phase
    1

    Participation criteria

    Sex
    Male
    Age
    18 - 50 years
    Accepts healthy volunteers
    Yes
    • Male subjects aged between 18 and 50 years inclusive.
    • Body mass index within the range 19-29.9kg/m2 (inclusive), with weight range of
    • As a result of the medical interview, physical examination or screening
    • investigations, the Investigator or appropriately qualified designee considers the
    Inclusion and exclusion criteria
    Inclusion criteria:

      Male subjects aged between 18 and 50 years inclusive.

      • Body mass index within the range 19-29.9kg/m2 (inclusive), with weight range of 50 kg-100 kg (inclusive).
      • Healthy (defined as individuals who are free from significant nasal, cardiac, pulmonary, gastrointestinal, hepatic, renal, haematological, malignancy, endocrine, neurological and psychiatric disease as determined by history, physical examination and screening investigations).
      • Non-smoking status as verified by urinary cotinine levels below 500 ng/mL cotinine at the screening visit. This can include ex-smokers who have given up smoking for >1 year.
      • Normal nasal examination as per Ear, Nose and Throat (ENT) assessment
      • No significant ECG abnormalities and QTc (B) <450 msec.
      • The subject is able and willing to give written informed consent to take part in the study and is available to complete all study measurements.
      • Male subjects must agree to abstain from or use a condom during sexual intercourse with female partners of childbearing potential, to prevent either pregnancy in the female partner or the possible exposure of a pregnant or lactating female to the investigational product from the male subject's semen. In addition, female partners of male subjects must use a reliable contraceptive method listed in the protocol, or they must refrain from sexual intercourse from the first dose of study medication until 84 days after the last dose.
    Exclusion criteria:

      As a result of the medical interview, physical examination or screening investigations, the Investigator or appropriately qualified designee considers the subject unfit for the study.

      • The subject has a history of drug or any other allergy, which, in the opinion of the Investigator or appropriately qualified designee, contraindicates their participation, including known or suspected personal history or family history of adverse reactions or hypersensitivity to anti histamines
      • The subject has participated in a study with a new molecular entity during the previous 3 months or any other study during the previous 2 months.
      • The subject regularly, or on average, drinks more than 21 units of alcohol a week or more than an average intake of 3 units per day.
      • The subject is currently taking regular (or a course of) medication, prescribed (including all beta-agonists) or not (including over the counter medication or herbal remedies such as St Johns Wort). Paracetamol is an exception and will be permitted at daily doses of up to 4g following the first dose of investigational product.
      • The subject has tested positive for hepatitis C antibody or hepatitis B surface antigen.
      • The subject has tested positive for HIV.
      • The subject has a positive drugs of abuse and alcohol test.
      • Donation during the study would result in >500mL of blood being donated over a 56 day period
      • Subjects with structural nasal abnormalities frequent nose bleeds, Perennial Allergic Rhinitis (PAR) and Seasonal Allergic Rhinitis (SAR) unless subjects with SAR are asymptomatic and it is outside of the pollen season
      • Subjects who are unable to comply with study procedures
      • Subject is the Investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the study
      • Vulnerable subjects (eg. persons kept in detention)

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    GSK Investigational Site
    Berlin, Berlin, Germany, 14050
    Status
    Will Be Recruiting
    Contact us

    Study documents

    Clinical study report
    Available language(s): English
    Download document(s)
    Scientific result summary
    Available language(s): English
    Download document(s)

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Refer to study documents

    Recruitment status
    Study complete
    Actual primary completion date
    Not applicable
    Actual study completion date
    2008-26-05

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Participate in clinical trial
    Additional information
    Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
    Click here
    Results for study HHI110157 can be found on the GSK Clinical Study Register.
    Click here
    Access to clinical trial data by researchers
    Visit website